Welcome to our dedicated page for PepGen SEC filings (Ticker: PEPG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PepGen Inc. (PEPG) SEC filings page on Stock Titan provides access to the company’s official disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq Global Select Market issuer, PepGen uses current reports on Form 8-K, registration statements, and other filings to report material events related to its clinical-stage biotechnology business.
Through these filings, investors can review Form 8-K reports covering topics such as financial results for recent quarters, material financing transactions, executive appointments, equity compensation changes, and investor communications. For example, PepGen has filed 8-Ks announcing quarterly financial results, the launch and pricing of an underwritten public offering under a shelf registration statement on Form S-3, and the appointment of a Chief Business and Legal Officer. Other 8-Ks describe an option repricing for employee stock options under the company’s 2020, 2022, and 2024 equity plans, and the furnishing of updated corporate presentations and clinical data summaries.
Filings also confirm that PepGen’s common stock, par value $0.0001 per share, is registered under Section 12(b) of the Exchange Act and trades on the Nasdaq Global Select Market under the symbol PEPG. Registration statements and prospectus supplements referenced in the filings outline how the company issues shares to fund its Enhanced Delivery Oligonucleotide (EDO) platform and clinical programs, including the FREEDOM-DM1 and FREEDOM2-DM1 trials of PGN-EDODM1 in myotonic dystrophy type 1.
On Stock Titan, these SEC documents are paired with AI-powered summaries that highlight key points from lengthy filings, helping users quickly identify items such as new financings, changes in executive leadership, or updates to clinical and investor presentations. Real-time updates from EDGAR, combined with AI explanations of complex legal and financial language, allow investors to follow PepGen’s regulatory history, capital-raising activities, and material corporate events without reading every line of each filing.